Conclusion: Combinations of docetaxel, a platinum salt, and trastuzumab are feasible and active in patients with advanced breast cancers that overexpress HER2. Overall response rates were higher and median time to progression was longer in the subset of patients whose tumors harbored HER2 gene amplification. Median times to progression were 9.9 months (95% CI = 8.3 to 13.1 months) and 12.7 months (95% CI = 8.6 to 15.5 months) for patients in the BCIRG 101 and UCLA-ORN studies, respectively. Responses were observed in 49 of 62 patients in the BCIRG 101 study (overall response rate = 79%, 95% confidence interval = 66% to 89%) and in 34 of 59 evaluable patients in the UCLA-ORN study (overall response rate = 58%, 95% CI = 44% to 70%). One patient in each study developed reversible congestive heart failure. Hematologic toxicities were more frequent in patients in the UCLA-ORN study than in patients in the BCIRG 101 study, whereas the reverse pattern was observed for non-hematologic toxicities. Both regimens were well tolerated, with manageable toxicities. Results: Patient characteristics were comparable between trials with the exception that 15% of the patients in the UCLA-ORN study had received previous adjuvant taxane therapy. HER2 gene amplification was determined by fluorescence in situ hybridization. Tumor measurements were obtained at baseline, after three cycles of chemotherapy, and then every 3 months. Trastuzumab was given on day 1, cycle 1 (4 mg/kg) and then continued weekly at 2 mg/kg for 1 year or until disease progression. min given on day 1 and then every 21 days.Patients received a median of six cycles of docetaxel at 75 mg/m 2 of body surface area and cisplatin (BCIRG 101 study) at 75 mg/m 2 or carboplatin (UCLA-ORN study) at AUC = 6 mg/mL Methods: Each study enrolled 62 patients with HER2-overexpressing tumors. The University of California at Los Angeles-Oncology Research Network (UCLA-ORN) and the Breast Cancer International Research Group (BCIRG) have conducted two phase II studies to evaluate docetaxel and trastuzumab in combination with either cisplatin or carboplatin for the treatment of women with advanced breast cancer that overexpresses HER2. Economic & Labour Market Review (2007), 48–56 doi:10.1057/: Preclinical data indicate that docetaxel, platinum salts, and the combination of both drugs are highly synergistic with the anti-HER2 antibody trastuzumab. Thearticle concludes by discussing which of the two measures might be better and then summarises the work that is in handto move AWE to National Statistic status. ![]() Each of the main methodologicaldifferences between the two measures is shown to contribute significantly to the differences between the two series. It then presents the preliminary results of the reconciliation project. ![]() article sets out the background to the project, describes the two measures and explains the main differencesbetween them. Sets out the background to the AWE/AEI reconciliation project, differentiating between thetwo measures, and presents preliminary results.This article presents the preliminary results of the AEI/AWE reconciliation project, a project which seeks to reconcile themovements in the two main measures of short-term earnings growth – the Average Earnings Index (AEI) and Average WeeklyEarnings (AWE).The.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |